MLSep 22, 2023
Multiply Robust Federated Estimation of Targeted Average Treatment EffectsLarry Han, Zhu Shen, Jose Zubizarreta
Federated or multi-site studies have distinct advantages over single-site studies, including increased generalizability, the ability to study underrepresented populations, and the opportunity to study rare exposures and outcomes. However, these studies are challenging due to the need to preserve the privacy of each individual's data and the heterogeneity in their covariate distributions. We propose a novel federated approach to derive valid causal inferences for a target population using multi-site data. We adjust for covariate shift and covariate mismatch between sites by developing multiply-robust and privacy-preserving nuisance function estimation. Our methodology incorporates transfer learning to estimate ensemble weights to combine information from source sites. We show that these learned weights are efficient and optimal under different scenarios. We showcase the finite sample advantages of our approach in terms of efficiency and robustness compared to existing approaches.
LGJul 25, 2021
Federated Causal Inference in Heterogeneous Observational DataRuoxuan Xiong, Allison Koenecke, Michael Powell et al.
We are interested in estimating the effect of a treatment applied to individuals at multiple sites, where data is stored locally for each site. Due to privacy constraints, individual-level data cannot be shared across sites; the sites may also have heterogeneous populations and treatment assignment mechanisms. Motivated by these considerations, we develop federated methods to draw inference on the average treatment effects of combined data across sites. Our methods first compute summary statistics locally using propensity scores and then aggregate these statistics across sites to obtain point and variance estimators of average treatment effects. We show that these estimators are consistent and asymptotically normal. To achieve these asymptotic properties, we find that the aggregation schemes need to account for the heterogeneity in treatment assignments and in outcomes across sites. We demonstrate the validity of our federated methods through a comparative study of two large medical claims databases.